Sage Journals: Discover world-class research

Abstract

This paper evaluates the effectiveness of a pharmaceutical-based drug information service (PBDIS). Four hundred ninety-five health care providers from all specialties throughout the United States and 1,000 Glaxo medical service representatives completed surveys designed to assess the effectiveness of the Drug Information Service (DIS) at Glaxo Inc. Health care practitioners and medical service representatives were satisfied with the services offered by Glaxo's PBDIS. Services offered were very useful, the DIS was reasonably accessible, and the responses provided appropriate information in an understandable and efficient manner. Nearly all respondents indicated they were likely to request information from the DIS in the future. The services offered by Glaxo's PBDIS are very useful to the individuals who use them. Health care providers should be aware of and use the services of Glaxo's PBDIS and familiarize themselves with the type of information a PBDIS can provide.

Keywords

Pharmaceutical-based drug information service Survey Health care providers

Get full access to this article

View all access options for this article.

References

Bauman

Fuentes

Drug information at Glaxo Inc. Drug Info J. 1989;23:95–103.

Baker

User survey of an industry-based drug information service. Drug Info J. 1990;24:235–243.

Bainbridge

D'Ambrosio

Petrick

Weiss

Pharmaceutical manufacturer's responses to drug information inquiries. Am J Hosp Pharm. 1982;39:1532–1534.

Bassin

Bilhuber

Functioning of a medical information unit within a large pharmaceutical organization: A methodological approach and review. Drug Info J. 1986;20:165–172.

Boyland

Providing drug information to health professionals and consumers: Role and responsibility of the pharmaceutical manufacturer. Hosp Pharm. 1983;18:211–216.

Collins

Drug information services at Burroughs-Wellcome Company. Am J Hosp Pharm. 1990;47:1991–1993.

Magnuson

Buchanan

Quan

Teichman

Drug information at Genentech. Am J Hosp Pharm. 1990;47:1993–1995.

Pfeil-Doyle

Jones

Oberlin

Benitez

Drug information at Eli Lilly and Company. Am J Hosp Pharm. 1990;47:1996–1998.

Gasperino

Drug information services at Pfizer Labs. Am J Hosp Pharm. 1990;47:1998–1999.

10.

Baker

Gurwich

DePew

Drug information services at The Upjohn Company. Am J Hosp Pharm. 1990;47:1999–2001.

11.

Burns

Phillips

Rowles

Provision of drug information — a company report. Drug Info J. 1983;17:105–111.

12.

Repchinsky

Godbout

Tierney

A quality assurance audit for a regional and a hospital drug information service. Am J Hosp Pharm. 1988;41:267–269.

13.

Hart

Miwa

Millares

A drug information service quality assurance audit. Hosp Formul. 1989;24:383–389.

14.

Sketris

Bishop

Somers

Baker

Developing a quality assurance program for drug information requests answered by staff pharmacists. Drug Info J. 1989;23:327–334.

15.

Golightly

Davis

Budwitz

Documenting the activity and effectiveness of a regional drug information center. Am J Hosp Pharm. 1988;45:356–361.

16.

Colvin

Drug information services provided by the pharmaceutical industry. Am J Hosp Pharm. 1990;47:1989–1990.

17.

Tse CST. Disclosure of product information by manufacturers. Am J Hosp Pharm. 1982;39:645–646.

18.

Hoffman

Gumbhir

Evaluation of an industry-based drug information service. Drug Info J. 1993;27:549–560.

Evaluation and Effectiveness of a Pharmaceutical-Based Drug Information Service

Abstract

Keywords

Get full access to this article

References